LGND: Summary for Ligand Pharmaceuticals Incorpor - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Tuesday, November 24, 2009, 5:54am EST - Canadian Markets open in 3 hours and 36 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Ligand Pharmaceuticals Inc. (LGND)

On Nov 23: 2.20 USD 0.00 (0.00%)

MORE ON LGND

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Ligand Pharmaceuticals Incorpor (NGM:LGND) Delayed quote data

Last Trade:	2.20 USD
Trade Time:	Nov 23
Change:	0.00 (0.00%)
Prev Close:	2.20
Open:	N/A
Bid:	2.15 x 100
Ask:	2.59 x 100
1y Target Est:	5.00

Day's Range:	N/A - N/A
52wk Range:	1.63 - 3.21
Volume:	0
Avg Vol (3m):	697,328
Market Cap:	248.64M
P/E (ttm):	N/A
EPS (ttm):	-0.68
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add LGND to Portfolio

Download Data

HEADLINES

•	5 Top Stocks at Half Price
	at Motley Fool (Mon 12:25pm)

•	LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
	EDGAR Online (Mon 12:07pm)

•	Ligand Presents New Preclinical Data on its Lead SARM Molecule LGD-4033 at the Gerontological Society of America Annual Meeting
	Business Wire (Fri, Nov 20)

•	LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
	EDGAR Online (Thu, Nov 19)

•	Ligand receives $2 million from Merck partnership
	AP (Thu, Nov 19)

•	Ligand Earns $2 Million in Milestone Payments from Merck & Co., Inc.
	Business Wire (Thu, Nov 19)

•	LIGAND PHARMACEUTICALS INC Financials
	EDGAR Online Financials (Fri, Nov 13)

•	Three Core Biotech Holdings: Isis, Ligand and Vical
	at Seeking Alpha (Mon, Nov 9)

•	LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement
	EDGAR Online (Mon, Nov 9)

•	LIGAND PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Mon, Nov 9)

•	New Star Analyst Rankings for Ligand Pharmaceuticals Incorpor
	StarMine (Sun, Nov 8)

More Headlines for LGND...

ANALYST

EPS Est (next year) (Dec-09) :	-0.12
EPS Est (in 2 years) (Dec-10) :	-0.06
Avg Rec (current)*:	3.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Ligand Pharmaceuticals Incorporated, a biotechnology company, focuses on the discovery and development of pharmaceuticals for the critical unmet medical needs in the United States.

Full Company Profile

Add to Portfolio

Email to a Friend

•